Home Cart Sign in  
Chemical Structure| 86541-74-4 Chemical Structure| 86541-74-4

Structure of Benazepril HCl
CAS No.: 86541-74-4

Chemical Structure| 86541-74-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Benazepril HCl is an ACE inhibitor, primarily used in treatment of hypertension. Benazepril HCl is the HCl form of Benazepril.

Synonyms: CGS14824A; Benazepril (hydrochloride); CGS 14824A HCl

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Benazepril HCl

CAS No. :86541-74-4
Formula : C24H29ClN2O5
M.W : 460.95
SMILES Code : O=C(CN1C([C@H](CCC2=C1C=CC=C2)N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)=O)O.[H]Cl
Synonyms :
CGS14824A; Benazepril (hydrochloride); CGS 14824A HCl
MDL No. :MFCD00895734
InChI Key :VPSRQEHTHIMDQM-FKLPMGAJSA-N
Pubchem ID :5362123

Safety of Benazepril HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00000620 Atherosclerosis ... More >> Cardiovascular Diseases Hypercholesterolemia Hypertension Diabetes Mellitus, Type 2 Diabetes Mellitus Coronary Disease Less << Phase 3 Completed - United States, Minnesota ... More >> Minneapolis Medical Research Foundation Minneapolis, Minnesota, United States, 55404 United States, New York Columbia University New York, New York, United States, 10027 United States, North Carolina Wake Forest University Winston-Salem, North Carolina, United States, 27106 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Tennessee Veterans Affairs Memphis, Tennessee, United States, 38104 United States, Washington University of Washington Seattle, Washington, United States, 98195 Canada, Ontario McMaster University Hamilton, Ontario, Canada Less <<
NCT01076205 - Completed - -
NCT01669434 - Completed - -
NCT01715584 Hypertension Phase 4 Recruiting December 31, 2019 Canada, Ontario ... More >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD    519 685 8500 ext 58525    Craig.Railton@lhsc.on.ca    Principal Investigator: Craig J Railton, MD, PhD          Sub-Investigator: Jonathan Fairbairn, BSc          Sub-Investigator: George Nicoloau, MD          Sub-Investigator: Robert Gros, PhD          Sub-Investigator: Jason Franklin, MD          Sub-Investigator: John Yoo, MD          Sub-Investigator: Kevin Fung, MD          Sub-Investigator: Anthony Nichols, MD          Sub-Investigator: Danielle McNeil, MD Less <<
NCT00170950 Hypertension Phase 3 Terminated(The study was termi... More >>nated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) Less << - United States, New Jersey ... More >> Novartis Pharmaceuticals E. Hanover, New Jersey, United States, 07936 Denmark sites in Denmark Denmark, Denmark Finland sites in Finland Finland, Finland Norway sites in Norway Norway, Norway Sweden sites in Sweden Sweden, Sweden Less <<
NCT01669434 Hypotension on Induction Phase 4 Completed - United States, Nebraska ... More >> University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less <<
NCT01867047 Adverse Effects of Angiotensin... More >>-converting-enzyme Inhibitors Hypotension Less << Not Applicable Terminated(Following an interi... More >>m analysis the study team felt that there was enough data that showed no significant difference.) Less << - United States, North Carolina ... More >> Duke University Durham, North Carolina, United States, 27710 Less <<
NCT00170950 - Terminated(The study was termi... More >>nated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) Less << - -
NCT01603940 Hypertension ... More >>Diabetes Mellitus Less << Phase 4 Completed - Brazil ... More >> Hospital Universitario Pedro Ernesto Rio de Janeiro, RJ, Brazil, 20551030 Less <<
NCT00171119 Hypertension ... More >>Diabetic Nephropathy Less << Phase 4 Terminated - Switzerland ... More >> Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT00000620 - Completed - -
NCT01867047 - Terminated(Following an interi... More >>m analysis the study team felt that there was enough data that showed no significant difference.) Less << - -
NCT00630708 Renal Insufficiency, Chronic Not Applicable Terminated(Significant differe... More >>nces observed between groups.) Less << - China, Guangdong ... More >> Renal Division, Nanfang Hospital,Southern Medical University Guangzhou, Guangdong, China, 510515 Less <<
NCT01603940 - Completed - -
NCT02532777 Henoch-Schoenlein Purpura Neph... More >>ritis Less << Phase 2 Recruiting July 2020 China, Jiangsu ... More >> Nanjing Children's Hospital Recruiting Nanjing, Jiangsu, China, 210000 Contact: Aihua Zhang, M.D.    +8618951769017    bszah@163.com Less <<
NCT01375322 Hypertension ... More >>Diabetes Mellitus, Type 2 Albuminuria Less << Phase 4 Completed - Taiwan ... More >> Chang Gung Memorial Hospital-Kaohsiung Kaohsiung, Taiwan, 833 Taichung Veterans General Hospital Taichung, Taiwan, 407 Tri-Service General Hospital Taipei, Taiwan, 114 Far Eastern Memorial Hospital Taipei, Taiwan, 220 Less <<
NCT00367978 Hypertension Phase 4 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals Corporation East Hanover, New Jersey, United States, 07936 Less <<
NCT00907374 Microalbuminuria Not Applicable Completed - United States, California ... More >> Charles Drew University Los Angeles, California, United States, 90059 Less <<
NCT00907374 - Completed - -
NCT02532790 Henoch-Schoenlein Purpura Neph... More >>ritis Less << Phase 2 Recruiting July 2020 China, Jiangsu ... More >> Nanjing Children's Hospital Recruiting Nanjing, Jiangsu, China, 210000 Contact: Aihua Zhang, M.D.    +8618951769017    bszah@163.com Less <<
NCT01095939 Renal Alteration Phase 3 Completed - Switzerland ... More >> Geneva University Hospitals Geneva, Switzerland Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland Less <<
NCT03591471 Henoch-Sch?nlein Purpura Nephr... More >>itis Less << Phase 1 Phase 2 Recruiting December 2018 China, Henan ... More >> Children's Hospital, The First Affiliated Hospital of HUTCM Recruiting Zhengzhou, Henan, China, 450000 Contact: Ying Ding, Director    +86-13503840642    dingying3236@sina.com    Contact: Xia Zhang, secretary    +86-13838276039    zhangxia_125@163.com    Principal Investigator: Ying Ding, Director          The First Affiliated Hospital of Henan University of Traditional Chinese Medicine Recruiting Zhengzhou, Henan, China, 450000 Contact: Ying Ding, MD    +86-371-66221361    dingying3236@sina.com    Contact: Xia zhang, MD    +86-371-13213210370    ardar123@sina.com    Principal Investigator: Jiansheng Li, MD Less <<
NCT01234922 Hypertension ... More >>Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 2 Terminated(slow accrual) - United States, North Carolina ... More >> Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 Less <<
NCT00234871 Hypertension ... More >>Diabetes Proteinuria Less << Phase 4 Completed - -
NCT00136851 Hypertension Phase 4 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00836576 Healthy Phase 1 Completed - United States, Missouri ... More >> Gateway Medical Research, Inc. St. Charles, Missouri, United States, 63301 Less <<
NCT00649597 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT00649038 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT01234922 - Terminated(slow accrual) - -
NCT00649402 Healhty Phase 1 Completed - United States, West Virginia ... More >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 Less <<
NCT00778674 Healthy Not Applicable Completed - United States, North Carolina ... More >> aaiPharma, Inc. Chapel Hill, North Carolina, United States, 27517 Less <<
NCT00836537 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT00834977 Healthy Phase 1 Completed - Canada, Quebec ... More >> Anapharm Inc. Montreal, Quebec, Canada, H3X H29 SFBC Anapharm Sainte-Foy, Quebec, Canada, G1V 2K8 Less <<
NCT00649519 Healthy Phase 1 Completed - United States, West Virginia ... More >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 Less <<
NCT00835367 Healthy Phase 1 Completed - Canada, Quebec ... More >> Anapharm Inc. Montreal, Quebec, Canada, H2X 2H9 SFBC Anapharm Sainte-Foy, Quebec, Canada, G1V 2K8 Less <<
NCT00835367 - Completed - -
NCT00834977 - Completed - -
NCT01155908 Healthy Phase 1 Completed - -
NCT01155895 Healthy Phase 1 Completed - -
NCT00778726 Healthy Not Applicable Completed - United States, North Carolina ... More >> aaiPharma, Inc Chapel Hill, North Carolina, United States, 27517 Less <<
NCT01505998 Fed Phase 1 Completed - India ... More >> Vimta Labs Ltd. Hyderabad, A.P, India, 500 051 Less <<
NCT01506011 Fasting Phase 1 Completed - India ... More >> Vimta Labs Ltd. Hyderabad, A.P, India, 500 051 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.85mL

2.17mL

1.08mL

21.69mL

4.34mL

2.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories